BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7922015)

  • 1. A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cells.
    Rubin J; Malley V; Ball ED
    J Hematother; 1994; 3(2):121-7. PubMed ID: 7922015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells.
    Nimgaonkar M; Kemp A; Lancia J; Ball ED
    J Hematother; 1996 Feb; 5(1):39-48. PubMed ID: 8646480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
    Passos-Coelho J; Ross AA; Davis JM; Huelskamp AM; Clarke B; Noga SJ; Davidson NE; Kennedy MJ
    Cancer Res; 1994 May; 54(9):2366-71. PubMed ID: 8162582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
    Rizzieri DA; Talbot JT; Long GD; Vredenburgh JJ; Gasparetto C; Smith CS; Colvin MO; Adams D; Morris A; Dodge R; Loftis J; Waters-Pick B; Reese M; Carawan H; Koh LP; Chao NJ
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):183-8. PubMed ID: 12652469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia.
    Miller CB; Rowlings PA; Zhang MJ; Jones RJ; Piantadosi S; Keating A; Armitage JO; Calderwood S; Harris RE; Klein JP; Lazarus HM; Linker CA; Sobocinski KA; Weisdorf D; Horowitz MM
    Exp Hematol; 2001 Nov; 29(11):1336-46. PubMed ID: 11698130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
    Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of 4-hydroperoxycyclophosphamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging.
    Zhong RK; Donnenberg AD; Rubin J; Ball ED
    Blood; 1994 Apr; 83(8):2345-51. PubMed ID: 7512845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
    Ericson SG; Colby E; Welch L; Ball ED
    Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
    Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
    Wiley JM; Yeager AM
    Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor.
    Zhong RK; Kozii R; Ball ED
    Br J Haematol; 1995 Oct; 91(2):269-74. PubMed ID: 8547061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
    Stiff PJ; Schulz WC; Bishop M; Marks L
    Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
    Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
    Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
    Newman A; Clutterbuck RD; DeLord C; Powles RL; Catovsky D; Millar JL
    J Investig Med; 1995 Jun; 43(3):269-74. PubMed ID: 7614073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction: workshop summary of the CD15 monoclonal antibody panel from the Fifth International Workshop on Leukocyte Antigens.
    Ball ED
    Eur J Morphol; 1995 Apr; 33(2):95-100. PubMed ID: 7488522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purging with 4-hydroperoxycyclophosphamide.
    Jones RJ
    J Hematother; 1992; 1(4):343-8. PubMed ID: 1345676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.